CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: LEUKAPHERESIS MARKET, BY PRODUCT
4.1 Overview
4.1.1 Market size and forecast
4.2 Devices
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Disposables
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
CHAPTER 5: LEUKAPHERESIS MARKET, BY METHOD
5.1 Overview
5.1.1 Market size and forecast
5.2 Centrifugation
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Membrane Separation
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Selective Adsorption
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
CHAPTER 6: LEUKAPHERESIS MARKET, BY APPLICATION
6.1 Overview
6.1.1 Market size and forecast
6.2 Therapeutic Applications
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Research Applications
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
CHAPTER 7: LEUKAPHERESIS MARKET, BY END USER
7.1 Overview
7.1.1 Market size and forecast
7.2 Blood Centers
7.2.1 Key market trends, growth factors and opportunities
7.2.2 Market size and forecast, by region
7.2.3 Market analysis by country
7.3 Hospitals
7.3.1 Key market trends, growth factors and opportunities
7.3.2 Market size and forecast, by region
7.3.3 Market analysis by country
7.4 Others
7.4.1 Key market trends, growth factors and opportunities
7.4.2 Market size and forecast, by region
7.4.3 Market analysis by country
CHAPTER 8: LEUKAPHERESIS MARKET, BY REGION
8.1 Overview
8.1.1 Market size and forecast
8.2 North America
8.2.1 Key trends and opportunities
8.2.2 North America Market size and forecast, by Product
8.2.3 North America Market size and forecast, by Method
8.2.4 North America Market size and forecast, by Application
8.2.5 North America Market size and forecast, by End User
8.2.6 North America Market size and forecast, by country
8.2.6.1 U.S.
8.2.6.1.1 Market size and forecast, by Product
8.2.6.1.2 Market size and forecast, by Method
8.2.6.1.3 Market size and forecast, by Application
8.2.6.1.4 Market size and forecast, by End User
8.2.6.2 Canada
8.2.6.2.1 Market size and forecast, by Product
8.2.6.2.2 Market size and forecast, by Method
8.2.6.2.3 Market size and forecast, by Application
8.2.6.2.4 Market size and forecast, by End User
8.2.6.3 Mexico
8.2.6.3.1 Market size and forecast, by Product
8.2.6.3.2 Market size and forecast, by Method
8.2.6.3.3 Market size and forecast, by Application
8.2.6.3.4 Market size and forecast, by End User
8.3 Europe
8.3.1 Key trends and opportunities
8.3.2 Europe Market size and forecast, by Product
8.3.3 Europe Market size and forecast, by Method
8.3.4 Europe Market size and forecast, by Application
8.3.5 Europe Market size and forecast, by End User
8.3.6 Europe Market size and forecast, by country
8.3.6.1 Germany
8.3.6.1.1 Market size and forecast, by Product
8.3.6.1.2 Market size and forecast, by Method
8.3.6.1.3 Market size and forecast, by Application
8.3.6.1.4 Market size and forecast, by End User
8.3.6.2 France
8.3.6.2.1 Market size and forecast, by Product
8.3.6.2.2 Market size and forecast, by Method
8.3.6.2.3 Market size and forecast, by Application
8.3.6.2.4 Market size and forecast, by End User
8.3.6.3 UK
8.3.6.3.1 Market size and forecast, by Product
8.3.6.3.2 Market size and forecast, by Method
8.3.6.3.3 Market size and forecast, by Application
8.3.6.3.4 Market size and forecast, by End User
8.3.6.4 Italy
8.3.6.4.1 Market size and forecast, by Product
8.3.6.4.2 Market size and forecast, by Method
8.3.6.4.3 Market size and forecast, by Application
8.3.6.4.4 Market size and forecast, by End User
8.3.6.5 Spain
8.3.6.5.1 Market size and forecast, by Product
8.3.6.5.2 Market size and forecast, by Method
8.3.6.5.3 Market size and forecast, by Application
8.3.6.5.4 Market size and forecast, by End User
8.3.6.6 Rest of Europe
8.3.6.6.1 Market size and forecast, by Product
8.3.6.6.2 Market size and forecast, by Method
8.3.6.6.3 Market size and forecast, by Application
8.3.6.6.4 Market size and forecast, by End User
8.4 Asia-Pacific
8.4.1 Key trends and opportunities
8.4.2 Asia-Pacific Market size and forecast, by Product
8.4.3 Asia-Pacific Market size and forecast, by Method
8.4.4 Asia-Pacific Market size and forecast, by Application
8.4.5 Asia-Pacific Market size and forecast, by End User
8.4.6 Asia-Pacific Market size and forecast, by country
8.4.6.1 Japan
8.4.6.1.1 Market size and forecast, by Product
8.4.6.1.2 Market size and forecast, by Method
8.4.6.1.3 Market size and forecast, by Application
8.4.6.1.4 Market size and forecast, by End User
8.4.6.2 China
8.4.6.2.1 Market size and forecast, by Product
8.4.6.2.2 Market size and forecast, by Method
8.4.6.2.3 Market size and forecast, by Application
8.4.6.2.4 Market size and forecast, by End User
8.4.6.3 India
8.4.6.3.1 Market size and forecast, by Product
8.4.6.3.2 Market size and forecast, by Method
8.4.6.3.3 Market size and forecast, by Application
8.4.6.3.4 Market size and forecast, by End User
8.4.6.4 Australia
8.4.6.4.1 Market size and forecast, by Product
8.4.6.4.2 Market size and forecast, by Method
8.4.6.4.3 Market size and forecast, by Application
8.4.6.4.4 Market size and forecast, by End User
8.4.6.5 South Korea
8.4.6.5.1 Market size and forecast, by Product
8.4.6.5.2 Market size and forecast, by Method
8.4.6.5.3 Market size and forecast, by Application
8.4.6.5.4 Market size and forecast, by End User
8.4.6.6 Rest of Asia-Pacific
8.4.6.6.1 Market size and forecast, by Product
8.4.6.6.2 Market size and forecast, by Method
8.4.6.6.3 Market size and forecast, by Application
8.4.6.6.4 Market size and forecast, by End User
8.5 LAMEA
8.5.1 Key trends and opportunities
8.5.2 LAMEA Market size and forecast, by Product
8.5.3 LAMEA Market size and forecast, by Method
8.5.4 LAMEA Market size and forecast, by Application
8.5.5 LAMEA Market size and forecast, by End User
8.5.6 LAMEA Market size and forecast, by country
8.5.6.1 Brazil
8.5.6.1.1 Market size and forecast, by Product
8.5.6.1.2 Market size and forecast, by Method
8.5.6.1.3 Market size and forecast, by Application
8.5.6.1.4 Market size and forecast, by End User
8.5.6.2 Saudi Arabia
8.5.6.2.1 Market size and forecast, by Product
8.5.6.2.2 Market size and forecast, by Method
8.5.6.2.3 Market size and forecast, by Application
8.5.6.2.4 Market size and forecast, by End User
8.5.6.3 South Africa
8.5.6.3.1 Market size and forecast, by Product
8.5.6.3.2 Market size and forecast, by Method
8.5.6.3.3 Market size and forecast, by Application
8.5.6.3.4 Market size and forecast, by End User
8.5.6.4 Rest of LAMEA
8.5.6.4.1 Market size and forecast, by Product
8.5.6.4.2 Market size and forecast, by Method
8.5.6.4.3 Market size and forecast, by Application
8.5.6.4.4 Market size and forecast, by End User
CHAPTER 9: COMPANY LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Key developments
CHAPTER 10: COMPANY PROFILES
10.1 Adacyte Therapeutics
10.1.1 Company overview
10.1.2 Company snapshot
10.1.3 Operating business segments
10.1.4 Product portfolio
10.1.5 Business performance
10.1.6 Key strategic moves and developments
10.2 AllCells, LLC.
10.2.1 Company overview
10.2.2 Company snapshot
10.2.3 Operating business segments
10.2.4 Product portfolio
10.2.5 Business performance
10.2.6 Key strategic moves and developments
10.3 Asahi Kasei Corporation
10.3.1 Company overview
10.3.2 Company snapshot
10.3.3 Operating business segments
10.3.4 Product portfolio
10.3.5 Business performance
10.3.6 Key strategic moves and developments
10.4 Charles River Laboratories International, Inc.
10.4.1 Company overview
10.4.2 Company snapshot
10.4.3 Operating business segments
10.4.4 Product portfolio
10.4.5 Business performance
10.4.6 Key strategic moves and developments
10.5 Cerus Corporation
10.5.1 Company overview
10.5.2 Company snapshot
10.5.3 Operating business segments
10.5.4 Product portfolio
10.5.5 Business performance
10.5.6 Key strategic moves and developments
10.6 Fresenius Kabi
10.6.1 Company overview
10.6.2 Company snapshot
10.6.3 Operating business segments
10.6.4 Product portfolio
10.6.5 Business performance
10.6.6 Key strategic moves and developments
10.7 Haemonetics Corporation
10.7.1 Company overview
10.7.2 Company snapshot
10.7.3 Operating business segments
10.7.4 Product portfolio
10.7.5 Business performance
10.7.6 Key strategic moves and developments
10.8 Macopharma
10.8.1 Company overview
10.8.2 Company snapshot
10.8.3 Operating business segments
10.8.4 Product portfolio
10.8.5 Business performance
10.8.6 Key strategic moves and developments
10.9 SB-Kawasumi Laboratories, Inc.
10.9.1 Company overview
10.9.2 Company snapshot
10.9.3 Operating business segments
10.9.4 Product portfolio
10.9.5 Business performance
10.9.6 Key strategic moves and developments
10.10 Terumo BCT, Inc.
10.10.1 Company overview
10.10.2 Company snapshot
10.10.3 Operating business segments
10.10.4 Product portfolio
10.10.5 Business performance
10.10.6 Key strategic moves and developments
TABLE 1. GLOBAL LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 2. LEUKAPHERESIS MARKET, FOR DEVICES, BY REGION, 2021-2031 ($MILLION)
TABLE 3. LEUKAPHERESIS MARKET FOR DEVICES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. LEUKAPHERESIS MARKET, FOR DISPOSABLES, BY REGION, 2021-2031 ($MILLION)
TABLE 5. LEUKAPHERESIS MARKET FOR DISPOSABLES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. GLOBAL LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 7. LEUKAPHERESIS MARKET, FOR CENTRIFUGATION, BY REGION, 2021-2031 ($MILLION)
TABLE 8. LEUKAPHERESIS MARKET FOR CENTRIFUGATION, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 9. LEUKAPHERESIS MARKET, FOR MEMBRANE SEPARATION, BY REGION, 2021-2031 ($MILLION)
TABLE 10. LEUKAPHERESIS MARKET FOR MEMBRANE SEPARATION, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 11. LEUKAPHERESIS MARKET, FOR SELECTIVE ADSORPTION, BY REGION, 2021-2031 ($MILLION)
TABLE 12. LEUKAPHERESIS MARKET FOR SELECTIVE ADSORPTION, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 13. GLOBAL LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 14. LEUKAPHERESIS MARKET, FOR THERAPEUTIC APPLICATIONS, BY REGION, 2021-2031 ($MILLION)
TABLE 15. LEUKAPHERESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 16. LEUKAPHERESIS MARKET, FOR RESEARCH APPLICATIONS, BY REGION, 2021-2031 ($MILLION)
TABLE 17. LEUKAPHERESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 18. GLOBAL LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 19. LEUKAPHERESIS MARKET, FOR BLOOD CENTERS, BY REGION, 2021-2031 ($MILLION)
TABLE 20. LEUKAPHERESIS MARKET FOR BLOOD CENTERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 21. LEUKAPHERESIS MARKET, FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)
TABLE 22. LEUKAPHERESIS MARKET FOR HOSPITALS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 23. LEUKAPHERESIS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 24. LEUKAPHERESIS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 25. LEUKAPHERESIS MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 26. NORTH AMERICA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 27. NORTH AMERICA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 28. NORTH AMERICA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 29. NORTH AMERICA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 30. NORTH AMERICA LEUKAPHERESIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 31. U.S. LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 32. U.S. LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 33. U.S. LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 34. U.S. LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 35. CANADA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 36. CANADA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 37. CANADA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 38. CANADA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 39. MEXICO LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 40. MEXICO LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 41. MEXICO LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 42. MEXICO LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 43. EUROPE LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 44. EUROPE LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 45. EUROPE LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 46. EUROPE LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 47. EUROPE LEUKAPHERESIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 48. GERMANY LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 49. GERMANY LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 50. GERMANY LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 51. GERMANY LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 52. FRANCE LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 53. FRANCE LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 54. FRANCE LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 55. FRANCE LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 56. UK LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 57. UK LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 58. UK LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 59. UK LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 60. ITALY LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 61. ITALY LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 62. ITALY LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 63. ITALY LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 64. SPAIN LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 65. SPAIN LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 66. SPAIN LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 67. SPAIN LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 68. REST OF EUROPE LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 69. REST OF EUROPE LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 70. REST OF EUROPE LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 71. REST OF EUROPE LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 72. ASIA-PACIFIC LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 73. ASIA-PACIFIC LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 74. ASIA-PACIFIC LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 75. ASIA-PACIFIC LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 76. ASIA-PACIFIC LEUKAPHERESIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 77. JAPAN LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 78. JAPAN LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 79. JAPAN LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 80. JAPAN LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 81. CHINA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 82. CHINA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 83. CHINA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 84. CHINA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 85. INDIA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 86. INDIA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 87. INDIA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 88. INDIA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 89. AUSTRALIA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 90. AUSTRALIA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 91. AUSTRALIA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 92. AUSTRALIA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 93. SOUTH KOREA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 94. SOUTH KOREA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 95. SOUTH KOREA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 96. SOUTH KOREA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 97. REST OF ASIA-PACIFIC LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 98. REST OF ASIA-PACIFIC LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 99. REST OF ASIA-PACIFIC LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 100. REST OF ASIA-PACIFIC LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 101. LAMEA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 102. LAMEA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 103. LAMEA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 104. LAMEA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 105. LAMEA LEUKAPHERESIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 106. BRAZIL LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 107. BRAZIL LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 108. BRAZIL LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 109. BRAZIL LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 110. SAUDI ARABIA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 111. SAUDI ARABIA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 112. SAUDI ARABIA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 113. SAUDI ARABIA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 114. SOUTH AFRICA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 115. SOUTH AFRICA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 116. SOUTH AFRICA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 117. SOUTH AFRICA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 118. REST OF LAMEA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 119. REST OF LAMEA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 120. REST OF LAMEA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 121. REST OF LAMEA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 122.ADACYTE THERAPEUTICS: COMPANY SNAPSHOT
TABLE 123.ADACYTE THERAPEUTICS: OPERATING SEGMENTS
TABLE 124.ADACYTE THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 125.ADACYTE THERAPEUTICS: NET SALES,
TABLE 126.ADACYTE THERAPEUTICS: KEY STRATERGIES
TABLE 127.ALLCELLS, LLC.: COMPANY SNAPSHOT
TABLE 128.ALLCELLS, LLC.: OPERATING SEGMENTS
TABLE 129.ALLCELLS, LLC.: PRODUCT PORTFOLIO
TABLE 130.ALLCELLS, LLC.: NET SALES,
TABLE 131.ALLCELLS, LLC.: KEY STRATERGIES
TABLE 132.ASAHI KASEI CORPORATION: COMPANY SNAPSHOT
TABLE 133.ASAHI KASEI CORPORATION: OPERATING SEGMENTS
TABLE 134.ASAHI KASEI CORPORATION: PRODUCT PORTFOLIO
TABLE 135.ASAHI KASEI CORPORATION: NET SALES,
TABLE 136.ASAHI KASEI CORPORATION: KEY STRATERGIES
TABLE 137.CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT
TABLE 138.CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: OPERATING SEGMENTS
TABLE 139.CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: PRODUCT PORTFOLIO
TABLE 140.CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: NET SALES,
TABLE 141.CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: KEY STRATERGIES
TABLE 142.CERUS CORPORATION: COMPANY SNAPSHOT
TABLE 143.CERUS CORPORATION: OPERATING SEGMENTS
TABLE 144.CERUS CORPORATION: PRODUCT PORTFOLIO
TABLE 145.CERUS CORPORATION: NET SALES,
TABLE 146.CERUS CORPORATION: KEY STRATERGIES
TABLE 147.FRESENIUS KABI: COMPANY SNAPSHOT
TABLE 148.FRESENIUS KABI: OPERATING SEGMENTS
TABLE 149.FRESENIUS KABI: PRODUCT PORTFOLIO
TABLE 150.FRESENIUS KABI: NET SALES,
TABLE 151.FRESENIUS KABI: KEY STRATERGIES
TABLE 152.HAEMONETICS CORPORATION: COMPANY SNAPSHOT
TABLE 153.HAEMONETICS CORPORATION: OPERATING SEGMENTS
TABLE 154.HAEMONETICS CORPORATION: PRODUCT PORTFOLIO
TABLE 155.HAEMONETICS CORPORATION: NET SALES,
TABLE 156.HAEMONETICS CORPORATION: KEY STRATERGIES
TABLE 157.MACOPHARMA: COMPANY SNAPSHOT
TABLE 158.MACOPHARMA: OPERATING SEGMENTS
TABLE 159.MACOPHARMA: PRODUCT PORTFOLIO
TABLE 160.MACOPHARMA: NET SALES,
TABLE 161.MACOPHARMA: KEY STRATERGIES
TABLE 162.SB-KAWASUMI LABORATORIES, INC.: COMPANY SNAPSHOT
TABLE 163.SB-KAWASUMI LABORATORIES, INC.: OPERATING SEGMENTS
TABLE 164.SB-KAWASUMI LABORATORIES, INC.: PRODUCT PORTFOLIO
TABLE 165.SB-KAWASUMI LABORATORIES, INC.: NET SALES,
TABLE 166.SB-KAWASUMI LABORATORIES, INC.: KEY STRATERGIES
TABLE 167.TERUMO BCT, INC.: COMPANY SNAPSHOT
TABLE 168.TERUMO BCT, INC.: OPERATING SEGMENTS
TABLE 169.TERUMO BCT, INC.: PRODUCT PORTFOLIO
TABLE 170.TERUMO BCT, INC.: NET SALES,
TABLE 171.TERUMO BCT, INC.: KEY STRATERGIES
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
